Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222728 · ClinicalTrials.gov registry record
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
A clinical trial of Neoplasms and Nervous System Disease, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- 5
- Enrollment target
- 1
- Study location
NCT01222728: Completed study of Neoplasms and Nervous System Disease, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT01222728 is a study of Neoplasms and Nervous System Disease that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 5 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01222728, a study of Neoplasms and Nervous System Disease, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * Neurofibromatosis type II (NF2) is associated with tumors of the nerves, brain, and spinal cord. Most people with NF2 develop vestibular schwannomas, or tumors on the hearing and balance nerves. As they grow, vestibular schwannomas can cause hearing loss and balance problems. If they grow very large they can cause more serious problems, such as seizures, loss of eyesight, weakness, speech problems, and problems with the sense of touch. More research is needed into NF2 because researchers do not completely understand why these tumors occur or what makes them grow over time. * Currently, tumor size is measured with magnetic resonance imaging (MRI) scans. However, MRI scans cannot predict how fast a tumor will grow. By using positron emission tomography (PET) scanning, researchers hope to be able to predict sudden growth spurts of tumors associated with NF2 and develop better treatment methods for this type of cancer. Objectives: \- To use magnetic resonance imaging and positron emission tomography to better understand the growth of brain tumors in people with neurofibromatosis type II. Eligibility: \- Individuals between 18 and 50 years of age who have been diagnosed with NF2 and have at least three untreated intracranial tumors. Design: * This study requires an initial set of outpatient visits to the NIH Clinical Center that will last 7 to 10 days. * Participants will have a physical and neurological examination and blood tests at the first visit. Participants will then have the following imaging studies to examine the tumors: * MRI scans of the brain * PET scans of the brain, combined with a computed tomography (CT) scan. The PET scans will be performed on separate days. Different contrast agents will be used for both scans, so researchers will inform participants if they need to fast or follow other procedures before having the scan. * After the initial imaging studies, participants will have additional MRI scans every 6 months for 2 years to t
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-09-22 |
| Est. Completion | 2015-06-03 |
What the finished NCT01222728 record still lists
NCT01222728 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT01222728 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01222728 about?
NCT01222728 is a clinical study titled "Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients". Background: * Neurofibromatosis type II (NF2) is associated with tumors of the nerves, brain, and spinal cord. Most people with NF2 develop vestibular schwannomas, or tumors on the hearing and balance nerves. As they grow, vestibular schwannomas can cause hearing loss and balance problems. If they ...
What is the current status of trial NCT01222728?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2010-09-22. Estimated completion is 2015-06-03.
What conditions does trial NCT01222728 study?
This clinical trial studies the following conditions: Neoplasms, Nervous System Disease, Vestibular Disease.
Who is sponsoring clinical trial NCT01222728?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01222728 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01222728's enrollment target sits among peer trials
5 159th of 158 the lowest of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI